Allegria Therapeutics develops mast cell-targeting therapies for allergic and inflammatory diseases. It coordinates the MastCURe consortium, backed by EUR 1.3 million in Eurostars funding, to tackle chronic urticaria.
- Announced on
- Round
- Grant
- Amount
- Amount not disclosed
- Location
- canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- Eurostars lead
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic